Prelude Therapeutics Inc (PRLD) stock

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 8/3075% above fair value

$3.52−0.26 (-6.88%)

Close on Nov 12, 2026Market cap $280.91MP/E –Yield –

Prelude Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Prelude Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Prelude Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PRLD.

Revenue growth220.3% · median 16.4%

Operating margin-300.6% · median -907.9%

Net margin-269.7% · median -578.2%

Advertisement
300 × 250

See a number that looks wrong?